In this program, we review a patient case to understand the intensification of therapy beyond basil insulin.
This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. It is approved by the Canadian Society of Endocrinology and Metabolism for a maximum of 0.25 credit(s).
|David C.W. Lau(MD, PhD, FRCPC)|
David Strain(MB, ChB, BSc (Hons) MD, FRCP)
Deanna Telner(MD, CCFP)
Elizabeth Rosolowsky(MD, MPH, FAAP, FRCPC)
Filip K. Knop(MD, PhD)
Jeffrey Habert(MD, CCFP, FCFP)
John Axler(MD, CCFP, FCFP)
Peter J. Lin(MD, CCFP)
Robyn L. Houlden(MD, FRCPC)
Thomas Round(MBBS, BSc, DRCOG, MRCGP)
Upon completion of this program, participants will be able to:
- Review when to consider intensification in therapy in a patient with type 2 diabetes on basal insulin
- Examine the different therapy options clinicians can consider adding to basal insulin therapy in type 2 diabetes